← SEC 公告列表 | MIRA SEC 公告 | MIRA PHARMACEUTICALS, INC.(MIRA)

重大事件 即時報告 8-K 2026-06-04

MIRA Pharmaceuticals 提交8-K,披露重大協議及自願性業務更新

於 SEC 網站開啟原文

AI 繁中摘要

MIRA Pharmaceuticals(MIRA PHARMACEUTICALS, INC.)於2026年6月4日向SEC提交了一份8-K申報,報告日期為2026年6月3日。是次申報涵蓋三項主要事項:簽訂重大確定協議(Item 1.01)、Regulation FD自願披露(Item 7.01)及相關財務報表與附件(Item 9.01)。 根據文件列表,公司隨附了一份重大協議(EX-10.1)及一份新聞稿或投資者簡報(EX-99.1)。該協議可能涉及合作、授權、融資或資產收購等戰略安排,但具體條款需參閱附件原文。同時,公司亦透過EX-99.1向市場披露了非強制性資訊,可能包括業務更新、臨床進展或管道里程碑。 公司總部位於佛羅里達州坦帕,主要業務為藥品製劑(SIC 2834),屬生命科學範疇。是次8-K申報未有提供管理層前瞻性展望或具體財務數字,但協議的簽訂往往意味著未來現金流、管線進度或合作關係的變化,投資者應密切關注協議細節及其對公司營運的影響。 💡重點提示:8-K屬即時披露,通常涉及重大事件;建議投資者仔細閱讀EX-10.1及EX-99.1附件,以評估該協議對股權結構、研發開支或盈利能力的潛在影響。如有後續修訂或補充申報,亦需跟進。
展開英文正文
EDGAR Filing Documents for 0001493152-26-027202

 
 
 
 
 
 
 

 
 
 SEC.gov
 
 

 
 EDGAR
 

 

 
 
 Latest Filings 
 

 
 Filings search tools
 

 
 
 Filing Detail

 
 SEC Home »

 Company Search »

 Current Page

 

 
 
 Form 8-K - Current report: 
 

 
 SEC Accession No. 0001493152-26-027202
 

 

 
 
 
 Filing Date

 2026-06-04

 Accepted

 2026-06-04 08:00:41

 Documents

 24

 

 
 Period of Report

 2026-06-03

 

 
 Items

 Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

 

 

 
  Interactive Data
 

 

 

 
 Document Format Files

 
 
 Seq
 Description
 Document
 Type
 Size
 

 
 1
 8-K
 form8-k.htm   iXBRL
 8-K
 27315
 

 
 2
 EX-10.1
 ex10-1.htm
 EX-10.1
 11076
 

 
 3
 EX-99.1
 ex99-1.htm
 EX-99.1
 18203
 

 
 4
 GRAPHIC
 ex10-1_001.jpg
 GRAPHIC
 410680
 

 
 5
 GRAPHIC
 ex10-1_002.jpg
 GRAPHIC
 377305
 

 
 6
 GRAPHIC
 ex10-1_003.jpg
 GRAPHIC
 398145
 

 
 7
 GRAPHIC
 ex10-1_004.jpg
 GRAPHIC
 409131
 

 
 8
 GRAPHIC
 ex10-1_005.jpg
 GRAPHIC
 447681
 

 
 9
 GRAPHIC
 ex10-1_006.jpg
 GRAPHIC
 464956
 

 
 10
 GRAPHIC
 ex10-1_007.jpg
 GRAPHIC
 428572
 

 
 11
 GRAPHIC
 ex10-1_008.jpg
 GRAPHIC
 288521
 

 
 12
 GRAPHIC
 ex10-1_009.jpg
 GRAPHIC
 525035
 

 
 13
 GRAPHIC
 ex10-1_010.jpg
 GRAPHIC
 121476
 

 
 14
 GRAPHIC
 ex10-1_011.jpg
 GRAPHIC
 126628
 

 
  
 Complete submission text file
 0001493152-26-027202.txt
  
 5737391
 

 
 

 
 Data Files

 
 
 Seq
 Description
 Document
 Type
 Size
 

 
 15
 XBRL SCHEMA FILE
 mira-20260603.xsd
 EX-101.SCH
 3047
 

 
 16
 XBRL LABEL FILE
 mira-20260603_lab.xml
 EX-101.LAB
 34239
 

 
 17
 XBRL PRESENTATION FILE
 mira-20260603_pre.xml
 EX-101.PRE
 22380
 

 
 27
 EXTRACTED XBRL INSTANCE DOCUMENT
 form8-k_htm.xml
 XML
 3337
 

 
 

 Mailing Address
 324 SOUTH HYDE PARK AVENUE, SUITE 350
 
TAMPA FL
33606 
 

 Business Address
 1200 BRICKELL AVENUE
 SUITE 1950 #1183
 
MIAMI FL
33131 
 813-369-5150
 

 MIRA PHARMACEUTICALS, INC. (Filer)
 CIK: 0001904286 (see all company filings)
EIN.: 853354547 | State of Incorp.: FL
Type: 8-K | Act: 34 | File No.: 001-41765 | Film No.: 261063247
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)